title: SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals.
abstract: The loss of dystrophin or its associated proteins results in the development of muscle wasting frequently associated with cardiomyopathy. Contractile cardiac tissue is injured and replaced by fibrous tissue or fatty infiltrates, leading to a progressive decrease of the contractile force and finally to end-stage heart failure. At the time symptoms appear, restoration of a functional allele of the causative gene might not be sufficient to prevent disease progression. Alterations in Ca(2+) transport and intracellular calcium levels have been implicated in many types of pathological processes, especially in heart disease. On the basis of a gene transfer strategy, we analyzed the therapeutic efficacy of primary gene correction in a δ-sarcoglycan (δ-SG)-deficient animal model versus gene transfer of the Ca(2+) pump hSERCA2a (human sarco-endoplasmic reticulum calcium ATPase 2a), at a symptomatic stage of heart disease. Our results strongly suggest that restoration of δ-SG at this stage of disease will not lead to improved clinical outcome. However, restoration of proper Ca(2+) handling by means of amplifying SERCA2a expression in the myocardium can lead to functional improvement. Abnormalities in Ca(2+) handling play an important role in disease progression toward heart failure, and increased SERCA2a levels appear to significantly improve cardiac contraction and relaxation. Beneficial effects persist at least over a period of 6 months, and the evolution of cardiac functional parameters paralleled those of normal controls. Furthermore, we demonstrate that a plasmid formulation based on amphiphilic block copolymers can provide a safe and efficient platform for myocardial gene therapies. The use of synthetic formulations for myocardial gene transfer might thus overcome one of the major hurdles linked to viral vectors, that is, repeat administrations.
authors.affiliation: 1 UPMC um76 , INSERM u974, CNRS umr7215, Institut de Myologie, 75013 Paris, France .
authors.forename: Sophie
authors.initials: S
authors.lastname: Bouyon
authors.forename: Véronique
authors.initials: V
authors.lastname: Roussel
authors.forename: Yves
authors.initials: Y
authors.lastname: Fromes
mesh_terms: D000818:Animals; D015316:Genetic Therapy; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008647:Mesocricetus; D009200:Myocardial Contraction; D009206:Myocardium / Q000473:pathology; D009928:Organ Specificity; D049031:Sarcoglycans / Q000172:deficiency*; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000235:genetics*; D013318:Stroke Volume; D017725:Ventricular Pressure
chemical_list: D049031:Sarcoglycans; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases